EmergingGrowth.com Celldex Theraprutics, Emerging Products, Bright Future.
EmergingGrowth.com Celldex Theraprutics, Emerging Products, Bright Future.

EmergingGrowth.com, a leading digital financial media company, Reports on Celldex Therepeutics (NASDAQ: CLDX) Discussions also include Dendreon Corp (NASDAQ: DNDN), Eli Lilly and Company (NYSE: LLY), and Roche Holding AG (NASDAQ: RHHBY).

 

Feature your company on EmergingGrowth.com.  Visit EmergingGrowth.com to find out how. 

Many times investors make their stock choices based on how they climb in value on the market. However, savvy investors should also consider the companies that are setting the stage for a series of future significant milestones. Their cutting-edge products will be tapped by thousands of people, and the companies may make for future solid investment.

Let’s look at a company that must be given credit for its contributions to the pharmaceutical industry. Its emerging products will benefit many people affected by breast cancer. One of its treatment studies include CDX-011. The treatment is a conjugate that binds to a specific protein that promotes the migration, invasion, and metastasis of the disease.  The company’s results demonstrate overall survival benefits.

CD-011 is the brainchild of Celldex Therapeutics (NASDAQ: CLDX). Since it announced the final results from its study, its stock has risen to $5 a share. While I think its great that Celldex is making progress with CD-011, that’s not the only thing that gets me excited by the stock. The breast cancer treatment is one in a line of studies carried out by the company. What piques my interest are the areas – outside breast cancer – that the company is studying. Another of its ongoing studies is on a vaccine that may act to promote anti-cancer effects in patients who have glioblastoma, a type of brain cancer.

“These events, coupled with ongoing activity in a number of other projects, will set the stage for a series of future milestones,” said Anthony Markucci, the CEO of Celldex while delivering the company’s third quarter report for the nine months ended September 30, 2012.

Celldex reported cash, cash equivalents, and marketing securities of $77.6 million, which the company believes will be sufficient to meet estimated working capital requirements and fund planned for program development into 2014. The decrease of $1.1 million from June 30, 2013 is due primarily to increased operational expenses during the quarter related to the vaccine on brain tumor. However, the cash outflows for these expenses were offset by the issuance of $2.0 million shares that raised net proceeds to Celldex of $10.9 million.

Sure, Celldex reported a net loss of $15 million for the third quarter of 2012 compared with a net loss of $11.8 million for the third quarter of 2011. It reported a net loss of $47.3 million for the nine months ended September 30, 2012, compared to a net loss of $32.1 million for the nine months ended September 30, 2011. But that is primarily due to increased operational expenses related to its studies.

Its competitors in the diagnostic substances industry are Dendreon Corp (NASDAQ: DNDN), Eli Lilly and Company (NYSE: LLY), and Roche Holding AG (NASDAQ: RHHBY). Trading at about $7.30 per share, its market cap is about $470 million. The decision as to whether to trade in Celldex in the first place rests with the individual trader. But if you want to place a pharmaceutical company on your watch list for 2013 and beyond, consider Celldex. Its emerging products may prove to be as strong as those produced by the world’s most valuable pharmaceutical companies.

 

About EmergingGrowth.com

 

By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.

 

Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack.  Sign up today to see what EmergingGrowth.com has to offer.

NEW:  Feature your company on EmergingGrowth.com.  Find out how by filling out our form at http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth

 

Contact:

EmergingGrowth.com

info@EmergingGrowth.com

305-323-5687

 

Join our Linked in Group

 

Like us on Facebook


 

Disclosure

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. In addition, Please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website. Always remember that investing in securities such as the ones listed within are for high-risk tolerant individuals only and not the general public. Whether you are an experienced investor or not, you should always consult with a stockbroker, financial advisor, or similar before purchasing or selling any securities viewed on any emails sent from EmergingGrowth.com or its website.
 

 

SOURCE EmergingGrowth.com

 

 

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here